A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Apilimod dimesylate (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors OrphAI Therapeutics
Most Recent Events
- 03 Sep 2024 Results published in the Brain.
- 20 Aug 2024 Planned End Date changed from 10 May 2024 to 10 Oct 2024.
- 24 Jan 2024 According to an OrphAI Therapeutics media release, Status changed from active, no longer recruiting to completed.